Hinge Health CFO sells 14,763 shares under plan

Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 14,763 shares of Class A common stock on February 23, 2026, at weighted average prices between roughly $38.40 and $40.46 per share.

Rhea-AI Filing Summary

Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 14,763 shares of Class A common stock on February 23, 2026, at weighted average prices between roughly $38.40 and $40.46 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. After these transactions, Budge directly owned 420,132 shares of Hinge Health Class A common stock.

Insider Trade Summary

Net Seller: 14,763 shares

Net Sell 3 txns

Insider Budge James

Role Chief Financial Officer

Sold 14,763 shs ($581K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	7,566	$38.7361	$293K
Sale	Class A Common Stock	6,297	$39.9033	$251K
Sale	Class A Common Stock	900	$40.4322	$36K

Holdings After Transaction: Class A Common Stock — 420,132 shares (Direct)

Footnotes (4)

1. F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $38.40 and the highest price at which shares were sold was $39.37. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $39.40 and the highest price at which shares were sold was $40.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. F4. Represents the weighted average sale price. The lowest price at which shares were sold was $40.40 and the highest price at which shares were sold was $40.46. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Hinge Health (HNGE) report for James Budge?

Hinge Health reported that Chief Financial Officer James Budge sold 14,763 shares of Class A common stock in open-market transactions on February 23, 2026. The sales were reported on a Form 4 insider trading filing with the Securities and Exchange Commission.

At what prices did the Hinge Health (HNGE) CFO sell his shares?

James Budge’s reported sales used weighted average prices of $38.7361, $39.9033, and $40.4322 per share. Footnotes note underlying sale price ranges from $38.40 to $40.46, with detailed trade breakdowns available from the reporting person upon request.

How many Hinge Health (HNGE) shares does the CFO still own after the sale?

After completing the reported transactions, Chief Financial Officer James Budge directly owned 420,132 shares of Hinge Health Class A common stock. This post-transaction holding is disclosed in the Form 4 as the total shares held following the final reported sale.

Were the Hinge Health (HNGE) insider stock sales under a Rule 10b5-1 plan?

Yes. A footnote explains that the reported sales were executed under a Rule 10b5-1 trading plan adopted by James Budge on June 12, 2025. Such plans allow pre-scheduled trades to occur regardless of later material nonpublic information.

How many separate sale transactions did the Hinge Health (HNGE) Form 4 include?

The Form 4 lists three separate open-market sale transactions in Hinge Health Class A common stock on February 23, 2026. Combined, these transactions totaled 14,763 shares sold, with each line item reflecting distinct weighted average sale prices and share amounts.

What type of security did the Hinge Health (HNGE) CFO sell in the Form 4 filing?

James Budge sold Hinge Health’s Class A Common Stock, which is the company’s primary equity security class. All three reported transactions on February 23, 2026, involved only non-derivative Class A common shares, not options or other derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 04:20 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Budge James

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/23/2026		S(1)		7,566	D	$38.7361(2)	427,329	D
Class A Common Stock	02/23/2026		S(1)		6,297	D	$39.9033(3)	421,032	D
Class A Common Stock	02/23/2026		S(1)		900	D	$40.4322(4)	420,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $38.40 and the highest price at which shares were sold was $39.37. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $39.40 and the highest price at which shares were sold was $40.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $40.40 and the highest price at which shares were sold was $40.46. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

	/s/ James Budge	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.